BioMatrix Specialty Pharmacy Awarded Preferred Provider Status for Immunoglobulin Therapies

BioMatrix Specialty Pharmacy announced today preferred network status with AscellaHealth for both intravenous and subcutaneous immunoglobulin (IG) therapy treating patients in the neurology, immunology, transplant, and rare disease space. The decision to include BioMatrix in the PBM’s national network was based on overall clinical expertise, extensive IG experience across a broad range of therapeutic categories, operational efficiencies, data reporting capabilities, and competitive pricing model. Effective October 6, 2020, BioMatrix is one of the specialty pharmacies selected by the PBM to hold preferred provider status.

AscellaHealth is a national Specialty PBM serving commercial, Medicare, and Medicaid health plans. The rapidly growing organization includes over 1 million covered lives and has earned a name by providing high quality care for patients and substantial cost savings for plan sponsors. 

Dea Belazi, President & CEO of AscellaHealth affirmed, “We are excited to be working with BioMatrix to support our IG patients and look forward to continuing to provide innovative service models.” 

BioMatrix CEO Nick Karalis stated “We are pleased to expand our partnership with AscellaHealth to include IG therapy, Our partnership creates value by uniting providers and other healthcare stakeholders to simplify the patient journey, improve patient health, and appropriately controlling specialty drug spend for plan sponsors of AscellaHealth.”

Related Posts

Subscribe Our Newsletter